Xilio Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
Xilio Therapeutics, Inc. carries a market capitalization of 49.06M, placing it among publicly traded companies globally. Its enterprise value stands at -72.63M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 49.06M |
| Enterprise Value | -72.63M |
Share Statistics
Xilio Therapeutics, Inc. currently has 5.78M shares outstanding.
| Shares Outstanding | 5.78M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 1.33, and the price-to-book ratio stands at -0.17.
| PE Ratio | N/A |
| PS Ratio | 1.33 |
| PB Ratio | -0.17 |
| P/TBV Ratio | 0.98 |
| P/FCF Ratio | -1.36 |
| P/OCF Ratio | -1.26 |
Enterprise Valuation
| EV / Sales | 0.78 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Xilio Therapeutics, Inc. maintains a current ratio of 3.59, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.59 |
| Quick Ratio | 3.50 |
| Debt / Equity | 9.15 |
| Debt / EBITDA | -0.16 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -23.43 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Xilio Therapeutics, Inc.'s stock has declined approximately -13.31924% over the past 52 weeks. The 50-day moving average sits at 8.29, while the 200-day moving average is 9.28.
| Beta (5Y) | N/A |
| 52-Week Price Change | -13.31924% |
| 50-Day Moving Average | 8.29 |
| 200-Day Moving Average | 9.28 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Xilio Therapeutics, Inc. generated 53.48M in revenue and converted that into -31.30M in net income, yielding earnings per share of -3.50. EBITDA reached -40.85M, while operating income came in at -42.24M.
| Revenue | 53.48M |
| Gross Profit | N/A |
| Operating Income | -42.24M |
| Pretax Income | -31.30M |
| Net Income | -31.30M |
| EBITDA | -40.85M |
| EBIT | -42.24M |
| Earnings Per Share (EPS) | -3.50 |
Balance Sheet
Xilio Therapeutics, Inc. holds 150.33M in cash and equivalents against 6.64M in total debt, resulting in a net debt position of -150.33M. Total book value stands at -428.32M, with working capital of 111.25M providing operational flexibility.
| Cash & Cash Equivalents | 150.33M |
| Total Debt | 6.64M |
| Net Debt | -150.33M |
| Equity (Book Value) | -428.32M |
| Book Value Per Share | -50.69 |
| Working Capital | 111.25M |
Cash Flow
Xilio Therapeutics, Inc. produced -56.31M in operating cash flow over the past twelve months. After subtracting -1.05M in capital expenditures, free cash flow totaled -57.36M - equivalent to -6.79 per share.
| Operating Cash Flow | -56.31M |
| Capital Expenditures | -1.05M |
| Free Cash Flow | -57.36M |
| FCF Per Share | -6.79 |
Margins
Xilio Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -78.98 and net profit margin of -58.52 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -78.98 |
| Pretax Margin | -58.52 |
| Profit Margin | -58.52 |
| EBITDA Margin | -76.39 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -166.95 |
| FCF Yield | -73.44 |
Stock Splits
Xilio Therapeutics, Inc.'s most recent stock split took place on March 16, 2026 with a 14:1 split ratio.
| Last Split Date | 3/16/2026 |
| Split Ratio | 14:1 |
Scores
Xilio Therapeutics, Inc. posts an Altman Z-Score of -2.91, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -2.91 |